Skip to content
Screener

Sarepta Therapeutics, Inc. SRPT Cost Of Goods Sold Excluding Amortization

Cost Of Goods Sold Excluding Amortization at other companies

Cal-Maine Foods logo
Cal-Maine FoodsCALM
$46.34M+4,009%
Twin Disc logo
Twin DiscTWIN
$69.56M+16.8%
Cal-Maine Foods logo
Cal-Maine FoodsCALM
$51.26M+4.5%
McCormick & Company, Incorporated logo
McCormick & Company, IncorporatedMKC
$1.06B
Ross Stores logo
Ross StoresROST
$3.87B+19.0%
Karman Holdings Inc. logo
Karman Holdings Inc.KRMN
$13.78M+122%

Segments

By segment

See full
All Other Segments$149.39M-2.1%

Other financials

Income statement

See full
Revenue$401.3M-34.3%
Operating income$13.3M-88.5%
Net income-$4.9M-102%
EPS (diluted)-$0.05-103%

Balance sheet

See full
Cash & equivalents$571.1M+11.9%
Total debt$198.2M-7.6%
Total equity$1.5B+8.8%
Total assets$3.2B-13.4%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$555.0K-98.3%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.77B+10.9%
Enterprise value$1.4B+7.5%
P/S0.9×

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin-6.9%
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-9.3%+2,662pp
Debt / equity0.1×0.0×
Current ratio4.4×+1.5×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept srpt:CostOfGoodsSoldExcludingAmortization.

The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:01 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335003
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Collaboration and other72,56297,968472,850231,301
Total revenues401,251611,0911,132,0541,355,947
Cost and expenses:
Cost of sales (excluding amortization of in-licensed rights)149,385152,558258,153290,122
Research and development91,258204,392245,218977,840
Selling, general and administrative107,600137,897216,551271,526
Litigation contingency charge39,00039,000
Amortization of in-licensed rights7176671,4081,268

Item 1. Financial Statements

FAQ

What is Sarepta Therapeutics, Inc.'s cost of goods sold excluding amortization?
Sarepta Therapeutics, Inc. (SRPT) reported cost of goods sold excluding amortization of $149.39M in Q2 2026.
How has Sarepta Therapeutics, Inc.'s cost of goods sold excluding amortization changed year-over-year?
Sarepta Therapeutics, Inc.'s cost of goods sold excluding amortization decreased by 2.1% year-over-year, from $152.56M to $149.39M.
What does cost of goods sold excluding amortization mean?
Cost Of Goods Sold Excluding Amortization as reported by Sarepta Therapeutics,, Inc. Common Stock.

Ask your AI about Sarepta Therapeutics, Inc.'s cost of goods sold excluding amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude